$3.00 Million in Sales Expected for Crispr Therapeutics AG (CRSP) This Quarter

Share on StockTwits

Wall Street brokerages expect that Crispr Therapeutics AG (NASDAQ:CRSP) will post $3.00 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Crispr Therapeutics’ earnings. The highest sales estimate is $4.00 million and the lowest is $2.00 million. Crispr Therapeutics posted sales of $1.09 million during the same quarter last year, which would indicate a positive year over year growth rate of 175.2%. The company is expected to announce its next earnings results on Tuesday, August 6th.

On average, analysts expect that Crispr Therapeutics will report full year sales of $7.83 million for the current financial year, with estimates ranging from $4.00 million to $15.00 million. For the next year, analysts anticipate that the business will report sales of $19.33 million, with estimates ranging from $8.00 million to $40.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last posted its earnings results on Monday, April 29th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.03). Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The firm had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $1.50 million. During the same quarter last year, the company posted ($0.62) EPS. The firm’s revenue was down 78.6% on a year-over-year basis.

CRSP has been the topic of a number of research analyst reports. Citigroup downgraded Crispr Therapeutics from a “neutral” rating to a “sell” rating and reduced their target price for the stock from $28.00 to $21.00 in a report on Tuesday, January 22nd. Zacks Investment Research cut Crispr Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 8th. BTIG Research boosted their target price on shares of Crispr Therapeutics from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Monday, April 22nd. Needham & Company LLC reiterated a “buy” rating and set a $62.00 target price on shares of Crispr Therapeutics in a research note on Wednesday, May 1st. Finally, BidaskClub upgraded shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $47.64.

In other Crispr Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $42.03, for a total transaction of $840,600.00. Following the completion of the sale, the chief executive officer now directly owns 186,542 shares in the company, valued at approximately $7,840,360.26. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, President Rodger Novak sold 14,780 shares of the business’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $40.00, for a total transaction of $591,200.00. Following the sale, the president now owns 1,033,227 shares of the company’s stock, valued at $41,329,080. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 128,693 shares of company stock valued at $5,222,495. Company insiders own 37.70% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Valeo Financial Advisors LLC boosted its stake in Crispr Therapeutics by 71.4% in the first quarter. Valeo Financial Advisors LLC now owns 725 shares of the company’s stock valued at $26,000 after acquiring an additional 302 shares in the last quarter. Flagship Harbor Advisors LLC lifted its holdings in shares of Crispr Therapeutics by 22.1% in the 1st quarter. Flagship Harbor Advisors LLC now owns 3,309 shares of the company’s stock worth $118,000 after acquiring an additional 600 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of Crispr Therapeutics by 6.0% in the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 11,034 shares of the company’s stock worth $395,000 after acquiring an additional 628 shares during the last quarter. Creative Planning lifted its holdings in shares of Crispr Therapeutics by 4.7% in the 1st quarter. Creative Planning now owns 15,486 shares of the company’s stock worth $553,000 after acquiring an additional 695 shares during the last quarter. Finally, Kore Private Wealth LLC acquired a new position in shares of Crispr Therapeutics in the 1st quarter worth approximately $27,000. Institutional investors and hedge funds own 43.71% of the company’s stock.

Shares of CRSP stock traded down $0.61 during midday trading on Friday, reaching $38.83. 296,800 shares of the stock were exchanged, compared to its average volume of 715,573. Crispr Therapeutics has a 1 year low of $22.22 and a 1 year high of $73.90. The company has a debt-to-equity ratio of 0.08, a quick ratio of 15.84 and a current ratio of 15.84. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -11.29 and a beta of 3.11.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Featured Article: Stock Selection – What is cash flow?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.